UNSPSC 51393302: Benafentrine

This classification denotes a phosphodiesterase inhibitor with the molecular formula C23H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DXB7KMD1F, chemically known as 4-(1,2,3,4,4qbeta,10bbeta-hexahydro-8,9-dimethoxy-2-methylbenzo(c)(1,6)naphthyridin-6-yl)acetanilid but generally known as benafentrine, which bears US NIH Compound Identifier 3084603. European Medicines Agency schedules Benafentrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05697MIG.

UNSPSC 51393302 Benafentrine is a Commodity code that in recent state and local activity maps to the procurement of pharmaceutical products and related health-system supplies — most concretely, naloxone (an opioid antagonist) and drug deactivation systems acquired by county health departments and state health agencies. The code shows procurement from local county government health authorities and state-level health and human services departments, with issuing bodies including Seminole County, Florida and the Texas Health and Human Services Commission.

Activity in the code appears geographically concentrated in Florida and Texas based on recent opportunities. Seminole County, Florida released an IFB on June 30, 2026 (IFB60459723LAS, due July 26, 2023) for annual purchase of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and includes E-Verify compliance, workers' compensation and commercial general liability insurance requirements, and a three-month probationary termination clause. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026 seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program under its Therapeutic Pharmacy Initiative, focused on establishing direct contracting relationships outside traditional pharmacy benefit managers and group purchasing organizations to improve prescription fulfillment and cost management; the RFI was exploratory in nature rather than a formal competitive solicitation.